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2008). Cyclooxygenase-Inhibiting Nitric Oxide Donators (CINODs) are a
new class of anti-arthritic drugs, which inhibit in a balanced way both
COX-1 and COX-2 while releasing nitric oxide, an important modulator of
vascular tone. We present here the effects of HCT 1026, a ﬂurbiprofen-
based CINOD, on chondrocytes, focusing on their catabolic and anabolic
activities, as well as activation of inﬂammatory pathways.
Methods: Isolated primary cultures of bovine and human articular chon-
drocytes (BAC and HAC) were preincubated with 10mM HCT 1026 or
ﬂurbiprofen and stimulated with Il-1b, in hypoxic or normoxic conditions.
Levels of mRNA for extracellular matrix proteins (aggrecan and collagen
type II) and matrix metalloproteases (MMPs), as well as TGFb receptor,
were determined by quantitative RT-PCR. NO release was assessed
on cell supernatants through the Griess reaction, and activities of NF-
úB and AP-1 were determined by electrophoretic mobility shift assay.
NO donation from HCT 1026 was evaluated by testing its vasorelaxing
activity in norepinephrine-precontracted rabbit aortic rings, in presence
or absence of 10 mM ODQ (a speciﬁc inhibitor of NO-dependent cGMP
formation).
Results: In hypoxic human articular chondrocytes stimulated with Il-1b,
both HCT 1026 and ﬂurbiprofen decreased expression of MMP-1 and -3
and TGF-b receptor by 20 to 40%. However, only HCT 1026 inhibited
Il-1b-dependent NO overproduction while did not affect basal aggrecan
or type II collagen mRNAs. Moreover, in BAC cultured in normoxic
conditions, HCT 1026 inhibited NF-úB and AP-1 activation, whereas
ﬂurbirprofen affected only AP-1 activity. HCT 1026, but not ﬂurbiprofen,
induced aorta vasorelaxation, with an EC50 of 5.9±1.2mM. ODQ pretreat-
ment abolished this effect, conﬁrming that vascular relaxation by HCT
1026 was based on its NO donating properties.
Conclusions: The CINOD HCT 1026 modulates chondrocytes catabolic
and anabolic metabolism, causing reduction of inﬂammatory markers
such as NO biosynthesis and activation of NF-úB. Moreover, HCT 1026
is able to donate biologically relevant nitric oxide, which can modulate
vascular tone. If conﬁrmed in in vivo studies, our data may provide
evidence that the ability of CINODs to donate NO have a potential
beneﬁcial impact on joint cartilage in OA patients.
542 EFFECTIVENESS OF MELOXICAM FOR TREATMENT OF
PAIN SYNDROME UNDER KNEE OSTEOARTHRITIS, LOW
BACK PAIN AND NECK PAIN IN ELDERLY PEOPLE
V.V. Povoroznyuk, M.A. Bystrytska, T.V. Orlyk. Institute of Gerontology
AMS Ukraine, Kiev, UKRAINE
Purpose: The research was aimed at evaluating of the effectiveness
of meloxicam (revmoxicam) for treatment of pain syndrome under knee
osteoarthritis, low back pain and neck pain in elderly people.
Methods: The patients were devided into three groups. The ﬁrst group
included 11 patients (aged 61.1±5.54 years) with neck pain, the second
group included 10 patients (aged 59.4±4.65 years) with low back pain and
the third group included 10 patients (aged 57.9±7.5 years) with knee os-
teoarthritis. All patients took meloxicam 15mg once per day during 5 days.
The following methods of study were used: Mc-Gill questionnaire, VAS,
WOMAC, determination of life quality by Roland-Morris questionnaire,
Neck disability index, EuroQol 5D scale.
Table 1. Dynamics of pain syndrome intensive after meloxicam treatment in patient of different
groups.
Index Group Before
treatment
After 5 days
of treatment
P Two weeks without
treatment
P
Index of pain, cm I 444±0.71 4.11±0.78 0.35 3.22±3.00 0.01
II 5.13±0.59 4.13±0.79 0.03 3.63±0.52 0.003
III 5.98±2.22 3.56±1.74 0.001 3.66±1.86 0.043
Descriptors, ball I 9.56±2.23 7.56±2.40 0.09 7.56±1.71 0.12
II 11.0±2.29 8.63±2.79 0.016 9.63±3.65 0.49
III 10.60±4.70 7.40±4.80 0.008 8.70±6.00 0.043
Ranks, ball I 18.78±5.17 13.22±5.28 0.07 12.00±3.52 0.03
II 23.50±6.71 16.88±6.61 0.006 18.88±8.06 0.36
III 23.30±16.10 16.50±11.70 0.01 18.50±15.0 0.57
Results: After 5 days of treatment patients, who was taking meloxicam,
noticed a signiﬁcant decrease of pain syndrome and it became low after
two weeks without treatment [Table].
Signiﬁcant decrease of all parameters of pain syndrome in second and
third groups was observed after 5 days. Intensity of pain syndrome was
also certainly decreased after two weeks without treatment in all groups
by some parameters. The difference of effectiveness of meloxicam in
patient with different diseases was observed by VAS: decrease of pain
syndrome in the ﬁrst group was – 7%, in the second groups – 17%,
and in the third group – 39%, F=2.76, p = 0.08. During the period of
research no patients who undergone treatment had registered any side
effects. There was no signiﬁcant difference between groups dealing with
the improvement of patient’s everyday activity.
Conclusions: It can be concluded that the meloxicam is effective and
safe in the treatment of low back pain syndrome, neck pain syndrome
and pain syndrome under knee osteoarthritis in elderly people. However,
the best effect of meloxicam was observed in patients with pain syndrome
under knee osteoarthritis that can be explained by the inﬂammatory
component of osteoarthritis pathogenesis.
543 EFFECTIVENESS OF TWO REGIMES OF GLUCOSAMINE
AND CHONDROITIN FOR TREATMENT OF PAIN SYNDROME
IN PATIENT WITH KNEE OSTEOARTHRITIS
V.V. Povoroznyuk, N.V. Grygoryeva, N.I. Dzerovych, T.A. Karasevskaya.
Institute of Gerontology AMS Ukraine, Kiev, UKRAINE
Purpose: The research was aimed at evaluating the effectiveness of two
regimes (continuous and interrupted) of Theraﬂex (500mg glucosamine
hydrochloride, 400mg chondroitin sulphate) in patients with knee os-
teoarthritis. Outcomes evaluated were pain, measures of performance
(function, activity of daily living, disability), employment status, range of
motion, and patient satisfaction/patient global perceived effects.
Methods: The ﬁrst group included 50 patients (aged 64.5±1.1 years)
with knee osteoarthritis (II stage, Kellgren-Lawrence’s classiﬁcation), who
took the drug in continuous regime during 9 months. The second group
included 50 patients with the same diagnosis (aged 64.6±1.0 years),
who took Theraﬂex twice during 3 months with 3 months interruption.
We examined the patients before the treatment and after 1, 3, 6, 9 and
12 months. Methods of study: Mc-Gill questionnaire, visual-analogical
scale (VAS), Lequen’s index, WOMAC, EuroQol-5D, 15-m. test, 6-min.
test.
Results: After three months of Theraﬂex’s treatment it was observed a
reliable decrease of pain syndrome in both groups by WOMAC, decrease
of constraint in movements, improvement of index of everyday activity,
VAS, 15-m.test. Examination of patients during 6, 9 and 12 months
show the effectiveness of both regimes of the therapy. Intensity of pain
syndrome and functional activity didn’t differ between the groups.
Conclusions: During 1-year period two regimes of Theraﬂex it was
established effective decrease of intensity of the pain syndrome and
improvement of everyday activity in patients with knee osteoarthritis. The
analgesic effect after taking Theraﬂex becomes noticeable after three
months and quality of life signiﬁcantly improved in patients of both groups.
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Purpose: The FLEXX trial studied the 6 month efﬁcacy and safety of a
non-avian form of IA hyaluronan for OA of the knee.
Methods: This was a randomized, saline-controlled, double-blind study
of 586 patients with primary OA of the knee were evaluated prior to and
following 3 weekly IA injections of hyaluronan or buffered saline. The
primary efﬁcacy measurement was pain recorded for the signal knee
after a 50-foot walk. Secondary variables included the 3 subscales of the
WOMAC, OARSI responder criteria, patient global assessment, use of
rescue medication, quality of life (SF-36), and safety.
Results: The ITT population included Hyaluronan n=291 and Saline
n = 295. There were 12% dropouts (Hyaluronan n=34; Saline n = 34).
Hyaluronan demographics: Age 62.5±10.6 (SD), women 63%, BMI 32±7,
Kellgren-Lawrence grade 2−41%, grade 3−59%, initial pain 56±22 with
minimal differences from the saline group. After 26 weeks, there was a
signiﬁcant improvement in pain recorded after a 50-foot walk (ANCOVA;
p = 0.028). Secondary variables were generally supportive of the primary
measurement. Serious adverse events occurred in Hyaluronan (n = 10)
and Saline (n = 9) groups. Arthralgia occurred in Hyaluronan (n = 27)
and Saline (n = 35) groups. Local injection site reactions occurred in
Hyaluronan (n = 2) and Saline (n = 1) groups.
Conclusions: IA hyaluronan was signiﬁcantly superior to saline for OA
of the knee over a 6-month period despite a large beneﬁcial effect of IA
saline.
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Figure 1. Change in pain scores on the 50-foot Walk Test from baseline
to week 26 ITT population.
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CARTILAGE IMPROVEMENT IN KNEE OSTEOARTHRITIS
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Purpose: Within the last few decades the concept of disease modifying
drugs (DMOAD) have been explored as alternative therapeutic treatment
modalities for osteoarthritis (OA). From the results of previous in vitro
and animal model studies, we have proposed that the spectrum of phar-
macological activities exhibited by Sodium Pentosan Polysulfate (NaPPS)
would qualify it as a DMOAD. However human clinical evidence to support
this proposition was a few. To assess the efﬁcacy, safety, and patient
satisfaction with a series of subcutaneous injections of NaPPS in the
patients who reported knee joint OA-associated pain, loss of ROM, and
disability that interfered with daily life and work
Methods: NaPPS is a semi-synthetic drug manufactured from beech-
wood hemicellulose by sulfate esteriﬁcation of the xylopyranose hydroxyl
groups. It has an average mean molecular weight of 5700Da. NaPPS in
this study was manufactured and supplied in injectable vials (100mg/ml)
by bene-Arzneimittel GmbH, Munich, Germany.
The open trial was undertaken with 20 patients with knee OA. Patients
were clinically assessed at entry and 1, 2, 3, 4, 8, 12, 16, 24 and 52 weeks
with physical examination and VAS for stiffness, pain at rest or walking,
ROM exercises, walking up and down stairs. A modiﬁed WOMAC OA
index was used for lifestyle parameters. Degradation of type II Collagen
(C2C) in Blood was measured with an ELISA kit, in accordance with the
manufacturer’s instructions.
Before the treatment, 2 weeks of NSAIDs washout period was made,
if necessary. Treatment consisted of 6 weekly subcutaneous injections
(sc) of NaPPS (2mg/kg). The protocol and written informed consent for
studies involving human subjects were approved by the review board in
our university. The statistical signiﬁcance, compared with the value at
entry, was determined by one way ANOVA and Dunnett’s method.
Results: The attribution of patients was as following: The average year
was 63 years old, All cases were female, were included in grade 1 to
2 according the classiﬁcation of Kellgren and Lawrence. The average of
WOMAC score at the ﬁrst visit was 37.0. All cases could be followed for
one year.
The dose of this PPS effected the blood coagulation test, but the value
in the study was within safety area. A tiny abnormal ﬁnding is noted in
serum chemistry: ie: serum triglyceride 1 hr after injection., but it was
reduced quickly in followed up period.
The hydroarthroses were reduced quickly in all cases. ROM of the knee
joint was improved. The clinical assessments, i.e. knee ﬂexion, pain at
walking, pain just after climb up and down stairs, pain just after ROM
exercise were improved signiﬁcantly. The concentration of C2C in Blood
were decreased signiﬁcantly. The clinical effect was continued for almost
one year.
The improvement of X ray ﬁndings could not detected.
In the previous vitro study, PPS reduced cartilage degradation by directly
and indirectly affecting these inﬂammatory mediators such as MMP-3.
PPS increased both the synthesis and the molecular weight of hyaluro-
nan. PPS had anti-inﬂamatory function. As the results of C2C in Blood,
quickly reducion of hydroarthroses and improvement of the knee joint
R.O.M., our result was compatible to the above vitro study
Conclusions: The availability, safety of NaPPS for knee osteo-arthlitis
patients and satisfaction level of patients was studied.
546 DUAL INHIBITION OF Il-1-INDUCED NF-úB ACTIVATION AND
iNOS ENZYME ACTIVITY, IN HUMAN CHONDROCYTES, BY
NATURAL AND COMMERCIAL a-PINENE
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Purpose: Our previous studies showed that the essential oil from the
leaves of Juniperus oxycedrus has potential value as a source of new
compounds capable of targeting the NF-úB signaling pathway in OA
chondrocytes. Upon fractionation, a fraction designated F3 proved to be
effective in reducing Il-1-induced NF-úB activation and NO production.
Since that fraction contains predominantly a racemic mixture of (+)-
and (−)-a-pinene, we compared its ability to inhibit those Il-1-induced
responses with those of pure commercial racemic a-pinene, (+)- and
(−)-a-pinene enantiomers, as well as with that of turpentine oil, another
natural source of racemic a-pinene. b-pinene was also tested.
Methods: The essential oil from Juniperus oxycedrus leaves was frac-
tionated by liquid chromatography and analyzed by gas chromatogra-
phy and gas chromatography-mass spectroscopy . a-pinene constitutes
approximately 92% of F3. Human chondrocytes were isolated from the
femoral condyles of multi-organ donors and used to evaluate the ability
of F3, turpentine oil and pure pinene isomers to inhibit Il-1-induced
NO production. The human chondrocytic cell line, C-28/I2, was used to
evaluate NF-úB activation. Both cell culture types were treated for 30min
with the essential oils or fraction, in two different dilutions, followed by
treatment with Il-1b (30 ng/ml) for 30min or 18 h to evaluate, respectively,
the cytoplasmic levels of IúB-a by western blot, or NO production by
the Griess reaction. To determine whether the test compounds have any
direct effect on iNOS enzyme activity, NO production was evaluated in
cell cultures pretreated with Il-1, 30 ng/ml, to induce the expression of the
enzyme before the addition of the test compounds. The MTT reduction
assay was used to rule out cytotoxic effects.
Table 1: Effect of pretreatment with natural and synthetic pinene isomers on Il-1-induced NO
production
NO production induced by Il-1b 30 ng/ml
Test compound dilution 1:7500 Test compound dilution 1:5000
No pretreatment 100.0±6.0%
Commercial racemic a-pinene 58.5±7.5% 40.6±3.4%
(+)-a-pinene 56.2±10.8% 30.1±2.9%
(−)-a-pinene 63.4±7.8% 57.3±6.0%
b-pinene 82.9±13.7% 76.7±14.7%
F3 51.4±7.3% 11.3±0.4%
Turpentine oil 71.8±3.5% 51.2±1.9%
Results: As shown in the table, F3, containing racemic a-pinene from
natural origin, is the most effective in reducing Il-1-induced NO produc-
tion (11.3%±0.4). When added to the chondrocyte cultures 18 h after
addition of Il-1, F3 also reduced NO production, although with a lower
magnitude than when added to the cell cultures before Il-1. Among the
pure compounds, (+)-a-pinene was the most effective in reducing Il-1-
induced NO production (30.1%±2.9), either when added before or after
Il-1. b-Pinene was only slightly active. F3 and (+)-a-pinene were also the
most effective in preventing Il-1-induced IúB-a degradation.
Conclusions: (+)-a-Pinene is more active than its (−) enantiomer. Since
F3 achieved a greater inhibition of both NF-úB activation and NO
production than the commercial racemic a-pinene or the (+)-a-pinene
enantiomer, it is possible that other minor components of that fraction
will also be active. The results obtained also indicate that a-pinene acts
